当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-10-31 , DOI: 10.1056/nejmoa2404625 Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, and Komal L. JhaveriFrom the Royal Marsden Hospital and Institute of Cancer Research (N.C.T.) and the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London (P. Schmid), London, and Roche, Welwyn Garden City (E.T., G.L.) — all in the United Kingdom, Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, South Korea (S.-A.I.), Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C. Saura), Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston (D...
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-10-31 , DOI: 10.1056/nejmoa2404625 Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, and Komal L. JhaveriFrom the Royal Marsden Hospital and Institute of Cancer Research (N.C.T.) and the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London (P. Schmid), London, and Roche, Welwyn Garden City (E.T., G.L.) — all in the United Kingdom, Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, South Korea (S.-A.I.), Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona (C. Saura), Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston (D...
Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degr...
中文翻译：
基于 Inavolisib 的 PIK3CA 突变晚期乳腺癌治疗
Inavolisib 是一种高效且选择性的磷脂酰肌醇 3-激酶复合物（由 PIK3CA 编码）的 p110 催化亚基的 α 亚型抑制剂，也促进...
更新日期：2024-10-31
中文翻译：
基于 Inavolisib 的 PIK3CA 突变晚期乳腺癌治疗
Inavolisib 是一种高效且选择性的磷脂酰肌醇 3-激酶复合物（由 PIK3CA 编码）的 p110 催化亚基的 α 亚型抑制剂，也促进...
京公网安备 11010802027423号